Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial

Agata Łaszewska, Timea Helter, Ashley Baldwin, Anthony J. Cleare, Philip J. Cowen, Jonathan Evans, Quentin J.M. Huys, Micheal Kurkar, Alexander C. Lewis, Neil Nixon, Abhinav Rastogi, Stuart Watson, John R. Geddes, Michael Browning, Judit Simon

Open source

DOI: 10.1016/j.lanepe.2025.101533
Published: 2026-02
Container: The Lancet Regional Health - Europe
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lanepe.2025.101533,
  title = {Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial},
  author = {Agata Łaszewska and Timea Helter and Ashley Baldwin and Anthony J. Cleare and Philip J. Cowen and Jonathan Evans and Quentin J.M. Huys and Micheal Kurkar and Alexander C. Lewis and Neil Nixon and Abhinav Rastogi and Stuart Watson and John R. Geddes and Michael Browning and Judit Simon},
  year = {2026},
  journal = {The Lancet Regional Health - Europe},
  doi = {10.1016/j.lanepe.2025.101533},
  url = {https://doi.org/10.1016/j.lanepe.2025.101533}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial
AU  - Agata Łaszewska
AU  - Timea Helter
AU  - Ashley Baldwin
AU  - Anthony J. Cleare
AU  - Philip J. Cowen
AU  - Jonathan Evans
AU  - Quentin J.M. Huys
AU  - Micheal Kurkar
AU  - Alexander C. Lewis
AU  - Neil Nixon
AU  - Abhinav Rastogi
AU  - Stuart Watson
AU  - John R. Geddes
AU  - Michael Browning
AU  - Judit Simon
PY  - 2026
JO  - The Lancet Regional Health - Europe
DO  - 10.1016/j.lanepe.2025.101533
UR  - https://doi.org/10.1016/j.lanepe.2025.101533
ER  -

APA

Łaszewska, A., Helter, T., Baldwin, A., Cleare, A. J., Cowen, P. J., Evans, J., Huys, Q. J., Kurkar, M., Lewis, A. C., Nixon, N., Rastogi, A., Watson, S., Geddes, J. R., Browning, M., & Simon, J. (2026). Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial. The Lancet Regional Health - Europe. https://doi.org/10.1016/j.lanepe.2025.101533

Source records

crossref · retrieved 2026-09-27T13:21:15.174Z